Sunday, June 21, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 198 of 1,261

  1. US 11633385

    Combination compositions for treatment of cancer

    RedHill Biopharma Ltd. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  2. US 11633405

    Steroid hormone pharmaceutical formulations

    Compass Therapeutics LLC · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  3. US 11634540

    Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method

    Nektar Therapeutics · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  4. US 11633416

    Oral formulations of CD73 compounds

    Arcus Biosciences, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  5. US 11634691

    Compositions and methods of treatment

    The Regents of the University of California · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  6. US 11634711

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  7. US 11634418

    Amino acid compounds and methods of use

    Pliant Therapeutics, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  8. US 11634730

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  9. US 11633377

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  10. US 11634433

    Macrocycles for use in treating disease

    TURNING POINT THERAPEUTICS, INC. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  11. US 11634443

    Treprostinil prodrugs

    United Therapeutics Corporation · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  12. US 11634480

    Human antibodies to GREM1

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  13. US 11633479

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  14. US 11633496

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  15. US 11633480

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  16. US 11633488

    Modified IL-2 polypeptides and uses thereof

    Bright Peak Therapeutics AG · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  17. US 11633483

    Modulators of PCSK9 expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  18. US 11633501

    Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  19. US 11634683

    Non-enzymatic method and milling device

    LIPOREGENA GMBH · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  20. US 11634413

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  21. US 11634688

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  22. US 11633503

    Delivery of oligonucleotide-functionalized nanoparticles

    Northwestern University · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  23. US 11633511

    Production of immune-response-stimulating aerosols by non-thermal plasma treatment of airborne pathogens

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  24. US 11634404

    Selective D3 dopamine receptor agonists and methods of their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.